Publishing research using ab4833? Please let us know so that we can cite the reference in this datasheet.

ab4833 has been referenced in 4 publications.

  • Wang H  et al. Inhibition of tumor vasculogenic mimicry and prolongation of host survival in highly aggressive gallbladder cancers by norcantharidin via blocking the ephrin type a receptor 2/focal adhesion kinase/paxillin signaling pathway. PLoS One 9:e96982 (2014). WB, ICC/IF ; Mouse . PubMed: 24811250
  • Lange K  et al. Combined lysophosphatidic acid/platelet-derived growth factor signaling triggers glioma cell migration in a tenascin-C microenvironment. Cancer Res 68:6942-52 (2008). WB ; Human . PubMed: 18757408
  • Demo SD  et al. Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome. Cancer Res 67:6383-91 (2007). PubMed: 17616698
  • Lange K  et al. Endothelin receptor type B counteracts tenascin-C-induced endothelin receptor type A-dependent focal adhesion and actin stress fiber disorganization. Cancer Res 67:6163-73 (2007). WB ; Human . PubMed: 17616673

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"